Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
zDHHC17 (HIP14) is a member of the human zDHHC family of protein S-palmitoyltransferases, characterized by a highly conserved DHHC cysteine-rich domain. The enzyme possesses an N-terminal ankyrin-repeat domain, which confers highly specific substrate recognition, notably for neuronal proteins such as huntingtin, SNAP25, CSP, ankyrin-B, and others. zDHHC17 catalyzes the post-translational modification of substrate proteins through the covalent linkage of palmitate (a fatty acid) to cysteine residues, regulating their membrane association, trafficking, stability, and signaling function. Its activity is pivotal for normal neurological development and synaptic function, and dysregulation or loss of zDHHC17 activity is linked to the pathogenesis of several neurological diseases, most notably Huntington's disease. Therapeutic targeting is challenging due to the broad physiological importance and the significant overlap among DHHC family members.
Irreversible inhibition of palmitoyltransferase active site cysteines (2-bromopalmitate). Interference with palmitoylation-dependent protein trafficking and localization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on zinc finger DHHC-type palmitoyltransferase 17 (zDHHC17).